60 Degrees Pharmaceuticals reported that all three enrolled patients in its open-label expanded access trial for relapsing babesiosis in immunosuppressed patients were cured after completing a tafenoquine-based regimen. The study evaluates ARAKODA (tafenoquine) combined with atovaquone and other antimalarials/antibiotics in patients who previously failed conventional antimicrobial regimens (NCT06478641). Tafenoquine dosing in the protocol can continue for up to one year until two consecutive negative Babesia PCR tests and symptom resolution are recorded, followed by confirmatory molecular testing including an FDA-approved RNA amplification assay used for blood donation screening. The company said these results build on a 2024 Yale report in Clinical Infectious Diseases that described 100% apparent treatment success in four patients treated with weekly tafenoquine added to an atovaquone-containing regimen (Clinical Infectious Diseases publication). Tafenoquine is not FDA-approved for babesiosis and is approved in the U.S. for malaria prophylaxis under the ARAKODA brand.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603110724PRIMZONEFULLFEED9669984) on March 11, 2026, and is solely responsible for the information contained therein.
Comments